Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2007-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.BMCL.2007.05.027PMID 17544271
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.

  2007cited by this paper
• Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors.

  2007cited by this paper
• 3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6.

  2006cited by this paper
• Novel checkpoint 1 inhibitors.

  2006cited by this paper
• Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors.

  2006cited by this paper
• Chk1 inhibitors for novel cancer treatment.

  2006cited by this paper
• 4-(Aminoalkylamino)-3-benzimidazole-quinolinones as potent CHK-1 inhibitors.

  2006cited by this paper
• Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors.

  2006cited by this paper
• Selective Chk1 inhibitors differentially sensitize p53‐deficient cancer cells to cancer therapeutics

  2006cited by this paper
• Features of selective kinase inhibitors.

  2005cited by this paper
• Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity.

  2005cited by this paper
• 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities.

  2005cited by this paper
• Sequence-selective DNA recognition: natural products and nature's lessons.

  2004cited by this paper
• Cell-cycle checkpoints and cancer

  2004cited by this paper
• Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide.

  2004cited by this paper
• Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening.

  2004cited by this paper
• Targeting the checkpoint kinases: chemosensitization versus chemoprotection

  2004cited by this paper
• Chk1 in the DNA damage response: conserved roles from yeasts to mammals.

  2004cited by this paper
• Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints.

  2004cited by this paper
• Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways

  2003cited by this paper
• Chk1 Mediates S and G2 Arrests through Cdc25A Degradation in Response to DNA-damaging Agents*

  2003cited by this paper
• Ataxia-telangiectasia-mutated (ATM) and NBS1-dependent Phosphorylation of Chk1 on Ser-317 in Response to Ionizing Radiation*

  2003cited by this paper
• Human Chk1 expression is dispensable for somatic cell death and critical for sustaining G2 DNA damage checkpoint.

  2003cited by this paper
• BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage

  2002cited by this paper
• DNA and its associated processes as targets for cancer therapy

  2002cited by this paper
• Mechanisms of in situ activation for DNA-targeting antitumor agents.

  2002cited by this paper
• ATR-Mediated Checkpoint Pathways Regulate Phosphorylation and Activation of Human Chk1

  2001cited by this paper
• Inhibition of the G2 DNA Damage Checkpoint and of Protein Kinases Chk1 and Chk2 by the Marine Sponge Alkaloid Debromohymenialdisine*

  2001cited by this paper
• The Chk1 Protein Kinase and the Cdc25C Regulatory Pathways Are Targets of the Anticancer Agent UCN-01*

  2000cited by this paper
• Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint.

  2000cited by this paper
• Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems.

  2000cited by this paper

• Synthesis and in vitro anticancer evaluation of 8b-hydroxy-1-(6-substitutedbenzo[d]thiazol-2-yl)-3-(3-substitutedphenyl)-1,8b-dihydroindeno[1,2-c]pyrazol-4(3aH)-ones

  2022cites this paper
• Recent Progress on Anticancer Agents Incorporating Pyrazole Scaffold.

  2021cites this paper
• Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors.

  2019cites this paper
• Novel N-benzylpiperidine carboxamide derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease.

  2019cites this paper
• An overview on the synthetic and medicinal perspectives of indenopyrazoles.

  2019cites this paper
• Design, synthesis and biological evaluation of 1, 4-dihydro indeno[1,2-c] pyrazole linked oxindole analogues as potential anticancer agents targeting tubulin and inducing p53 dependent apoptosis.

  2018cites this paper
• An application of CIFAP for predicting the binding affinity of Chk1 inhibitors derived from 2‐aminothiazole‐4‐carboxamide

  2017cites this paper
• Design, Synthesis, and Biological Evaluation of 1-Methyl-1,4-dihydroindeno[1,2-c]pyrazole Analogues as Potential Anticancer Agents Targeting Tubulin Colchicine Binding Site.

  2016cites this paper
• Computational studies on the binding mechanism between triazolone inhibitors and Chk1 by molecular docking and molecular dynamics.

  2015cites this paper
• Combining docking-based comparative intermolecular contacts analysis and k-nearest neighbor correlation for the discovery of new check point kinase 1 inhibitors

  2015cites this paper
• Discovery of Check Point Kinase 1 (Chk1) Inhibitors as Potential Anticancer Agents Using Ligand-Based Modelling and Virtual Screening

  2015cites this paper
• Methyl 3-((6-methoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-yl)amino)benzoate (GN39482) as a tubulin polymerization inhibitor identified by MorphoBase and ChemProteoBase profiling methods.

  2015cites this paper
• Characterization of the Cytotoxic Activity ODE-adefovir in AML

  2015cites this paper
• Challenging the gold standard for 3D-QSAR: template CoMFA versus X-ray alignment

  2014cites this paper
• Bioluminescent properties of obelin and aequorin with novel coelenterazine analogues

  2014cites this paper
• Synthesis of aryl-substituted or aryl-fused N-hydroxyethyl and N-hydroxymethypyrazole derivatives as potential ligands for the estrogen receptor

  2013cites this paper
• Molecular docking and 3D-QSAR studies on checkpoint kinase 1 inhibitors

  2013cites this paper
• Pyrazole scaffold: a remarkable tool in the development of anticancer agents.

  2013cites this paper
• N-benzyl-5-phenyl-1H-pyrazole-3-carboxamide promotes vascular endothelial cell angiogenesis and migration in the absence of serum and FGF-2

  2011cites this paper
• 3D-QSAR studies of checkpoint kinase 1 inhibitors based on molecular docking and CoMFA

  2010cites this paper
• G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

  2008cites this paper
• Pyrrolocarbazoles as checkpoint 1 kinase inhibitors.

  2008cites this paper
• Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors.

  2007cites this paper
• Cyanopyridyl containing 1,4-dihydroindeno[1,2-c]pyrazoles as potent checkpoint kinase 1 inhibitors: improving oral biovailability.

  2007cites this paper